Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 01-Oct-24 8:00 PM View:  | Fairmount Funds Management ... Director | Dianthus Therapeutics, Inc.... (DNTH) | 27-Sep-24 | Disposition (other) | 62,146 | -- | -- | (2%) 2.76M to 2.7M | |
| 01-Apr-24 6:21 PM View: | Fairmount Funds Management ... Director | Dianthus Therapeutics, Inc.... (DNTH) | 01-Apr-24 | Disposition (other) | 58,857 | -- | -- | (2%) 2.82M to 2.76M | |
| 01-Apr-24 6:21 PM View: | Fairmount Funds Management ... Director | Dianthus Therapeutics, Inc.... (DNTH) | 01-Apr-24 | Acquisition (other) | 58,857 | -- | -- | 2% 2.76M to 2.82M | |
| 24-Jan-24 7:04 PM View: | Moulder Leon O Jr Director | Dianthus Therapeutics, Inc.... (DNTH) | 22-Jan-24 | Grant | 166,667 | $12.00 | $2,000,000.00 | 13% 1.27M to 1.44M | |
| 24-Jan-24 7:02 PM View: | Fairmount Funds Management ... Director 10% Owner | Dianthus Therapeutics, Inc.... (DNTH) | 22-Jan-24 | Grant | 834,334 | $12.00 | $10,012,000.00 | 43% 1.93M to 2.76M | |
| 24-Jan-24 6:55 PM View: | Meng Lei Director | Dianthus Therapeutics, Inc.... (DNTH) | 22-Jan-24 | Grant | 1,500,000 | $12.00 | $18,000,000.00 | 123% 1.22M to 2.72M | |
| 03-Oct-23 4:00 PM View: | Fairmount Funds Management ... Director 10% Owner | Dianthus Therapeutics, Inc.... (DNTH) | 29-Sep-23 | Purchase | 24,670 | $13.63 | $336,252.00 | 1% 1.9M to 1.93M | |
| 28-Sep-23 5:09 PM View: | Fairmount Funds Management ... Director 10% Owner | Dianthus Therapeutics, Inc.... (DNTH) | 26-Sep-23 | Purchase | 30,000 | $13.15 | $394,500.00 | 2% 1.87M to 1.9M | |
| 25-Sep-23 4:15 PM View: | Randhawa Simrat Chief Medical Officer | Dianthus Therapeutics, Inc.... (DNTH) | 22-Sep-23 | Purchase | 2,000 | $13.20 | $26,400.00 | 100% 2.0K to 4.0K | |
| 25-Sep-23 4:15 PM View: | Randhawa Simrat Chief Medical Officer | Dianthus Therapeutics, Inc.... (DNTH) | 21-Sep-23 | Purchase | 2,000 | $13.20 | $26,400.00 | 100% 0 to 2.0K | |
| 21-Sep-23 4:23 PM View: | Fairmount Funds Management ... Director 10% Owner | Dianthus Therapeutics, Inc.... (DNTH) | 19-Sep-23 | Purchase | 30,000 | $13.20 | $396,000.00 | 2% 1.84M to 1.87M | |
| 13-Sep-23 9:17 PM View: | Fairmount Funds Management ... Director 10% Owner | Dianthus Therapeutics, Inc.... (DNTH) | 13-Sep-23 | Purchase | 9,367 | $11.76 | $110,156.00 | < 1% 3.67M to 3.68M | |
| 13-Sep-23 9:17 PM View: | Fairmount Funds Management ... Director 10% Owner | Dianthus Therapeutics, Inc.... (DNTH) | 12-Sep-23 | Purchase | 14,887 | $10.85 | $161,524.00 | < 1% 3.65M to 3.67M | |
| 09-Feb-23 4:30 PM View: | Third Rock Ventures Iv, L.P. 10% Owner | Dianthus Therapeutics, Inc.... (DNTH) | 08-Feb-23 | Sale | 1,500,000 | $0.82 | $1,230,000.00 | (33%) 4.56M to 3.06M | |
| 09-Feb-23 4:30 PM View: | Third Rock Ventures Iv, L.P. 10% Owner | Dianthus Therapeutics, Inc.... (DNTH) | 07-Feb-23 | Sale | 2,200,000 | $0.83 | $1,826,000.00 | (33%) 6.76M to 4.56M | |
| 02-Dec-22 4:23 PM View: | Deardorf Caren Chief Commercial Officer | Dianthus Therapeutics, Inc.... (DNTH) | 30-Nov-22 | Grant | 3,000 | $0.94 | $2,820.00 | 18% 16.76K to 19.76K | |
| 02-Dec-22 4:23 PM View: | Gardner Jason See Remarks Director | Dianthus Therapeutics, Inc.... (DNTH) | 30-Nov-22 | Grant | 3,000 | $0.94 | $2,820.00 | < 1% 941.95K to 944.95K | |
| 02-Dec-22 4:23 PM View: | Mahoney Stephen F. See Remarks | Dianthus Therapeutics, Inc.... (DNTH) | 30-Nov-22 | Grant | 3,000 | $0.94 | $2,820.00 | 21% 14.26K to 17.26K | |
| 02-Dec-22 4:26 PM View: | Beetham Thomas W. See Remarks | Dianthus Therapeutics, Inc.... (DNTH) | 30-Nov-22 | Grant | 3,000 | $0.94 | $2,820.00 | 18% 16.9K to 19.9K | |
| 02-Dec-22 4:19 PM View: | Stants Kristen Chief People Officer | Dianthus Therapeutics, Inc.... (DNTH) | 30-Nov-22 | Grant | 3,000 | $0.94 | $2,820.00 | 17% 17.26K to 20.26K | |
| 06-Jun-22 4:06 PM View: | Stants Kristen Chief People Officer | Dianthus Therapeutics, Inc.... (DNTH) | 31-May-22 | Grant | 3,000 | $0.99 | $2,970.00 | 21% 14.26K to 17.26K | |
| 06-Jun-22 4:05 PM View: | Deardorf Caren Chief Commercial Officer | Dianthus Therapeutics, Inc.... (DNTH) | 31-May-22 | Grant | 3,000 | $0.99 | $2,970.00 | 22% 13.76K to 16.76K | |
| 06-Jun-22 4:05 PM View: | Gardner Jason See Remarks Director | Dianthus Therapeutics, Inc.... (DNTH) | 31-May-22 | Grant | 3,000 | $0.99 | $2,970.00 | < 1% 938.95K to 941.95K | |
| 06-Jun-22 4:05 PM View: | Beetham Thomas W. See Remarks | Dianthus Therapeutics, Inc.... (DNTH) | 31-May-22 | Grant | 3,000 | $0.99 | $2,970.00 | 22% 13.9K to 16.9K | |
| 20-Sep-21 5:02 PM View: | Mahoney Stephen F. See Remarks | Dianthus Therapeutics, Inc.... (DNTH) | 16-Sep-21 | Market Sale | 5,736 | $6.73 | $38,603.30 | (29%) 20.0K to 14.26K | (16%) |
| 20-Sep-21 5:00 PM View: | Nichols David Wayne Chief Technical Officer | Dianthus Therapeutics, Inc.... (DNTH) | 16-Sep-21 | Market Sale | 5,694 | $6.73 | $38,320.60 | (28%) 20.0K to 14.31K | (16%) |
| 20-Sep-21 5:00 PM View: | Beetham Thomas W. See Remarks | Dianthus Therapeutics, Inc.... (DNTH) | 16-Sep-21 | Market Sale | 6,103 | $6.73 | $41,073.20 | (31%) 20.0K to 13.9K | (16%) |
| 20-Sep-21 5:00 PM View: | Gardner Jason See Remarks | Dianthus Therapeutics, Inc.... (DNTH) | 16-Sep-21 | Market Sale | 14,340 | $6.73 | $96,508.20 | (2%) 953.29K to 938.95K | (16%) |
| 20-Sep-21 5:08 PM View: | Stants Kristen Chief People Officer | Dianthus Therapeutics, Inc.... (DNTH) | 16-Sep-21 | Market Sale | 5,736 | $6.73 | $38,603.30 | (29%) 20.0K to 14.26K | (16%) |
| 20-Sep-21 5:00 PM View: | Olson Lisa See Remarks | Dianthus Therapeutics, Inc.... (DNTH) | 16-Sep-21 | Market Sale | 5,736 | $6.73 | $38,603.30 | (29%) 20.0K to 14.26K | (16%) |
| 20-Sep-21 5:02 PM View: | Deardorf Caren Chief Commercial Officer | Dianthus Therapeutics, Inc.... (DNTH) | 16-Sep-21 | Market Sale | 6,238 | $6.73 | $41,981.70 | (31%) 20.0K to 13.76K | (16%) |
| 16-Sep-21 7:40 PM View: | Gardner Jason See Remarks Director | Dianthus Therapeutics, Inc.... (DNTH) | 14-Sep-21 | Grant | 50,000 | -- | -- | 6% 903.29K to 953.29K | |
| 16-Sep-21 7:43 PM View: | Olson Lisa See Remarks | Dianthus Therapeutics, Inc.... (DNTH) | 14-Sep-21 | Grant | 20,000 | -- | -- | 100% 0 to 20.0K | |
| 16-Sep-21 7:39 PM View: | Beetham Thomas W. See Remarks | Dianthus Therapeutics, Inc.... (DNTH) | 14-Sep-21 | Grant | 20,000 | -- | -- | 100% 0 to 20.0K | |
| 16-Sep-21 7:42 PM View: | Stants Kristen Chief People Officer | Dianthus Therapeutics, Inc.... (DNTH) | 14-Sep-21 | Grant | 20,000 | -- | -- | 100% 0 to 20.0K | |
| 16-Sep-21 7:41 PM View: | Mahoney Stephen F. See Remarks | Dianthus Therapeutics, Inc.... (DNTH) | 14-Sep-21 | Grant | 20,000 | -- | -- | 100% 0 to 20.0K | |
| 16-Sep-21 7:39 PM View: | Nichols David Wayne Chief Technical Officer | Dianthus Therapeutics, Inc.... (DNTH) | 14-Sep-21 | Grant | 20,000 | -- | -- | 100% 0 to 20.0K | |
| 16-Sep-21 7:41 PM View: | Deardorf Caren Chief Commercial Officer | Dianthus Therapeutics, Inc.... (DNTH) | 14-Sep-21 | Grant | 20,000 | -- | -- | 100% 0 to 20.0K | |
| 23-Sep-21 10:00 PM View: | Borisy Alexis Director | Dianthus Therapeutics, Inc.... (DNTH) | 26-Aug-21 | Acquisition (other) | 4,100 | -- | -- | 100% 0 to 4.1K | |
| 26-Aug-21 5:54 PM View: | Third Rock Ventures Iv, L.P. 10% Owner | Dianthus Therapeutics, Inc.... (DNTH) | 25-Aug-21 | Disposition (other) | 1,250,000 | -- | -- | (16%) 8.01M to 6.76M | |
| 16-Feb-21 6:15 PM View: | Atlas Venture Fund X, L.P. 10% Owner | Dianthus Therapeutics, Inc.... (DNTH) | 11-Feb-21 | Disposition (other) | 968,726 | -- | -- | (24%) 4.12M to 3.15M | |
| 01-Jul-20 4:48 PM View: | Booth Bruce Director | Dianthus Therapeutics, Inc.... (DNTH) | 29-Jun-20 | Market Purchase | 1,250,000 | $8.00 | $10,000,000.00 | 30% 4.12M to 5.37M | (4%) |
| 10-Jan-20 5:01 PM View: | Gardner Jason See Remarks Director | Dianthus Therapeutics, Inc.... (DNTH) | 10-Jan-20 | Market Sale (Planned) | 11,200 | $15.25 | $170,800.00 | (1%) 914.49K to 903.29K | 50% |
| 03-Jan-20 4:01 PM View: | Davis John C. Jr Chief Medical Officer | Dianthus Therapeutics, Inc.... (DNTH) | 02-Jan-20 | Option Exercise | 11,294 | $9.49 | $107,180.00 | 136% 8.3K to 19.6K | |
| 03-Jan-20 4:01 PM View: | Davis John C. Jr Chief Medical Officer | Dianthus Therapeutics, Inc.... (DNTH) | 02-Jan-20 | Market Option Sale (Planned) | 11,294 | $15.04 | $169,817.00 | (58%) 19.6K to 8.3K | 49% |
| 03-Jan-20 4:01 PM View: | Gardner Jason See Remarks Director | Dianthus Therapeutics, Inc.... (DNTH) | 02-Jan-20 | Market Sale (Planned) | 2,800 | $15.10 | $42,280.00 | (< 1%) 917.29K to 914.49K | 49% |
| 26-Dec-19 4:12 PM View: | Isacson Christina K. Chief Business Officer | Dianthus Therapeutics, Inc.... (DNTH) | 24-Dec-19 | Market Sale (Planned) | 4,463 | $16.01 | $71,452.60 | (5%) 88.25K to 83.79K | 52% |
| 26-Dec-19 4:11 PM View: | Zdraveski Zoran See Remarks | Dianthus Therapeutics, Inc.... (DNTH) | 24-Dec-19 | Market Sale (Planned) | 7,902 | $16.00 | $126,432.00 | (6%) 135.91K to 128.01K | 52% |
| 26-Dec-19 10:13 AM View: | Zdraveski Zoran See Remarks | Dianthus Therapeutics, Inc.... (DNTH) | 23-Dec-19 | Market Sale (Planned) | 4,181 | $16.03 | $67,021.40 | (3%) 140.09K to 135.91K | 52% |
| 23-Dec-19 4:41 PM View: | Gardner Jason See Remarks Director | Dianthus Therapeutics, Inc.... (DNTH) | 23-Dec-19 | Market Sale (Planned) | 2,897 | $15.10 | $43,754.60 | (< 1%) 920.19K to 917.29K | 49% |
